| Literature DB >> 16257982 |
Yoke W Kow1, Gaobin Bao, Brenda Minesinger, Sue Jinks-Robertson, Wolfram Siede, Yu Lin Jiang, Marc M Greenberg.
Abstract
2-deoxyribonolactone (L) and 2-deoxyribose (AP) are abasic sites that are produced by ionizing radiation, reactive oxygen species and a variety of DNA damaging agents. The biological processing of the AP site has been examined in the yeast Saccharomyces cerevisiae. However, nothing is known about how L is processed in this organism. We determined the bypass and mutagenic specificity of DNA containing an abasic site (AP and L) or the AP analog tetrahydrofuran (F) using an oligonucleotide transformation assay. The tetrahydrofuran analog and L were bypassed at 10-fold higher frequencies than the AP lesions. Bypass frequencies of lesions were greatly reduced in the absence of Rev1 or Polzeta (rev3 mutant), but were only marginally reduced in the absence of Poleta (rad30 mutant). Deoxycytidine was the preferred nucleotide inserted opposite an AP site whereas dA and dC were inserted at equal frequencies opposite F and L sites. In the rev1 and rev3 strains, dA was the predominant nucleotide inserted opposite these lesions. Overall, we conclude that both Rev1 and Polzeta are required for the efficient bypass of abasic sites in yeast.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16257982 PMCID: PMC1275587 DOI: 10.1093/nar/gki926
Source DB: PubMed Journal: Nucleic Acids Res ISSN: 0305-1048 Impact factor: 16.971
Figure 1Structures of abasic sites used in this study. AP = apurinic/apyrimidinic lesion, 2-deoxyribose; F = abasic site analog, tetrahydrofuran; L = C1′-oxidized abasic site, 2-deoxyribonolactone.
DNA sequences of the lys2ΔA746 target site and the oligonucleotides used for transformation
A portion of the non-coding strand of the lys2ΔA746 allele is given, which is complementary to the coding strand sequence of the transforming oligonucleotides (LysA30-X). The dash in the lys2ΔA746 sequence corresponds to position of the frameshift mutation. The additional nucleotide present in each oligonucleotide is indicated in bold type.
F, tetrahydrofuran; S, 2-deoxyribose; L, 2-deoxyribonolactone.
Yeast strains used in this study
| Strains | Genotype | Source |
|---|---|---|
| SJR922 | ( | |
| SJR1777 | MATa | ( |
| SJR1777 WS4 | MATa | This study |
| SJR1777 WS5 | MATa | This study |
| SJR1777 WS6 | MATa | This study |
Transformation efficiency at the Lys2A746 locus
| Strain | No oligonucleotide | LysA30-R (300 pm) | LysA30 (300 pm) |
|---|---|---|---|
| WT | 58 ± 9 | 57 ± 8 | 8186 ± 1388 |
| ( | 62 ± 11 | 55 ±10 | 8880 ± 1470 |
Bypass frequencies for various abasic sites
| Bypass frequency (% of | |||
|---|---|---|---|
| F | Lactone | AP | |
| apn1 | 0.318 ± 0.038 (100) | 0.234 ± 0.14 (100) | 0.034 ± 0.008 (100) |
| apn1 rad30 | 0.274 ± 0.033 (86.2) | 0.272 ± 0.076 (117.4) | 0.024 ± 0.009 (70.6) |
| apn1 rev1 | 0.114 ± 0.042 (35.8) | 0.033 ± 0.029 (14.1) | 0.017 ± 0.009 (50) |
| apn1 rev3 | 0.116 ± 0.019 (36.5) | 0.034 ± 0.011 (14.5) | 0.013 ± 0.005 |
Bypass frequency = (No. of lesion)/(No. of control).
No. of lesions = number of transformants obtained with lesion-containing oligonucleotide minus number of transformants obtained with lysA30R.
No. of controls = number of transformants obtained with oligonucleotide LysA30 minus number of transformants obtained with lysA30R; n = numberof transformation experiments.
an = 5.
bn = 3.
cBypass frequency was determined by DNA sequencing.
Nucleotide insertions opposite abasic sites
| Strains | % Nucleotide inserted (no.) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AP | F | L | ||||||||||
| dA | dG | dC | dT | dA | dG | dC | dT | dA | dG | dC | dT | |
| apn1 | 32.0 (8) | — | 68.0 (17) | — | 51.7 (15) | 3.4 (1) | 41.4 (12) | 3.4 (1) | 56.7 (17) | — | 43.3 (13) | — |
| apn1 rad30 | 19.1 (4) | — | 80.9 (17) | — | 65.0 (13) | 5.0 (1) | 25.0 (5) | 5.0 (1) | 47.4 (9) | 5.3 (1) | 47.4 (9) | — |
| apn1 rev1 | 63.6 (14) | 9.1 (2) | 18.2 (4) | 9.1 (2) | 93.8 (15) | — | 6.2 (1) | — | 90.9 (20) | — | 9.1 (2) | — |
| apn1 rev3 | 81.8 (18) | 13.6 (3) | 4.5 (1) | — | 100 (31) | — | — | — | 81.0 (17) | — | 14.3 (3) | 4.8 (1) |
AP, deoxyribose; F, tetrahydrofuran; L, 2-deoxyribonolactone; no., number of transformants.